194
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Bioequivalence studies and sugar-based excipients effects on the properties of new generic ketoconazole tablets formulations and stability evaluation by using direct compression method

, , , , , , , , , & show all
Pages 530-539 | Received 24 Aug 2008, Accepted 17 Feb 2009, Published online: 30 Mar 2009

References

  • Battu SK, Repka MA, Majumdar S, Madhusudan RY. Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants. Drug Dev Ind Pharm 2007,33:1225–1232.
  • Oshima T, Sonoda R, Ohkuma M, Sunada H. Preparation of rapidly disintegrating tablets containing itraconazole solid dispersions. Chem Pharm Bull 2007,55:1557–1562.
  • Gonnissen Y, Gonçalves SI, De Geest BG, Remon JP, Vervaet C. Process design applied to optimize a directly compressible powder produced via a continuous manufacturing process. Eur J Pharm Biopharm 2008,68:760–770.
  • Souto C, Rodriguez A, Parajes S, Martınez-Pacheco R. A comparative study of the utility of two superdisintegrants in microcrystalline cellulose pellets prepared by extrusion-spheronization. Eur J Pharm Biopharm, 2005,61:94–99.
  • Mizumoto T, Masuda Y, Yamamoto T, Yonemochi E, Terada K. Formulation design of a novel fast-disintegrating tablet. Int J Pharm 2005,306:83–90.
  • Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basic for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995,12:413–420.
  • Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004;58:265–278.
  • Pedersen PV, Gobburu JVS, Meyers MC, Straughn AB. Carbamazepine level-A in vitro-in vivo correlation (IVIVC): A scaled convolution based predictive approach. Biopharm Drug Dispos 2000,21:1–6.
  • Uppoor VRS. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release 2001,72:127–132.
  • UNIFESP, Oswaldo Ramos Foundation, Kidney and Hypertension Hospital. Bioequivalence study of two ketocanazole 200 mg tablet formulations. São Paulo, Brazil:UNIFESP; 2000.
  • Pascucci VL, Bennet J, Narang PK, Chatterji DC. Quantitation of Ketoconazole in biological fluids using high performance liquid chromatography. J Pharm Sci 1983,12:1467–1469.
  • Yuen KH, Peh KK. Simple high performance liquid chromatographic method for determination of ketoconazole in human plasma. J Chromatogr B Biomed Sci 1998,715:436–440.
  • Mosharraf M, Nyström C. The effect of particle size shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm 1995,122:35–47.
  • Mosharraf M, Nyström C. The effect of dry mixing on the apparent solubility of hydrophobic, sparingly soluble drugs. Eur J Pharm Sci 1999,9:145–156.
  • Viseras C, Salem II, Galan ICR, Galan A, Galindo AL. The effect of recrystallization on the crystal growth, melting point and solubility of ketoconazole. Thermochimica acta 1995,268:143–151.
  • Yang Z, Wong CS, Yang C, Jiang ZH, Zhao Z, Liu L. Control release effects of binders used in pills of traditional Chinese medicine herbs. Chem Pharm Bull 2006,54:188–195.
  • Spiegeleer BD, Vooren LV, Voorspoels J, Thoné; D, Rosier J. Dissolution stability and IVIVC investigation of bucal tablet. Anal Chim Acta 2001,446:345–351.
  • Shah U, Ausburger L. Multiple sources of sodium starch glycolate: Evaluation of functional equivalence and development of standard performance tests. Pharm Dev Technol 2002,7:345–359.
  • Hwang RR, Kowalski DL. Design of experiments for formulation development. PharmTech.com; 1 December 2005.
  • Zhao N, Augsburger LL. The influence of product brand-to-brand variability on superdisintegrant performance. A case study with croscarmellose sodium. Pharm Dev Technol 2006,11:179–185.
  • Joshi A, Duriez X. Added functionality excipients: An answer to challenging formulations. Pharm Technol 2004;34:12–19.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.